Anti-Osteopontin (SPP1), human Exon 4 [LF-161] Antibody

This rabbit IgG polyclonal antibody was generated against peptide (exon 4) and is specific for human Osteopontin (SPP1).

Highlights:

  • Recognizes human Osteopontin (SPP1) - Epitope LYNKYPDAVATWLNPDPSQKQNLLAPN
  • Suitable for Immunohistochemistry and Western Blot applications

Osteopontin is a phosphoglycoprotein synthesized in a variety of tissues and cells. It was originally identified as a bone matrix protein and subsequently as a cytokine produced by various immune and transformed cell lines. OPN is a biomarker for various types of cancers and inflammatory diseases. Excessive or dysregulated OPN expression has been linked to the pathogenesis of both autoimmune disorders such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, atherosclerosis and other inflammatory diseases including cardiovascular disease, chronic obstructive pulmonary disease, inflammatory bowel disease, liver disease and asthma.

From the laboratory of Larry W. Fisher, PhD, National Institute of Dental and Craniofacial Research/NIH.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
ENH092-FP
Anti-Osteopontin (SPP1), human Exon 4 [LF-161] Antibody
100uL In stock
Regular Price:$306.00
On Sale:

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.

Specifications

Product Type: Antibody
Antigen: Osteopontin (SPP1), human
Accession ID: P10451.1
Molecular Weight: 35422 Da
Clonality: Polyclonal
Clone Name: LF-161
Reactivity: Human
Immunogen: Peptide (exon 4)
Species Immunized: Rabbit
Epitope: LYNKYPDAVATWLNPDPSQKQNLLAPN
Buffer: Whole serum
Tested Applications: WB 1:2000, IHC 1:200
Storage: -80C
Shipped: Dry Ice

Provider
From the laboratory of Larry W. Fisher, PhD, National Institute of Dental and Craniofacial Research.
References
  1. Zduniak K, Ziolkowski P, Ahlin C, Agrawal A, Agrawal S, Blomqvist C, Fjällskog ML, Weber GF. Nuclear osteopontin-c is a prognostic breast cancer marker. Br J Cancer. 2015 Feb 17;112(4):729-38.
  2. Zduniak K, Agrawal A, Agrawal S, Hossain MM, Ziolkowski P, Weber GF. Osteopontin splice variants are differential predictors of breast cancer treatment responses. BMC Cancer. 2016 Jul 11;16:441.

If you publish research with this product, please let us know so we can cite your paper.

Loading...